Product news from the 11/28/06 news brief

Share this article:
Teva Pharmaceutical said the FDA has approved its generic versions of GlaxoSmithKline’s Zofran (ondansetron). Zofran is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy (cancer therapy that causes vomiting) and prevention of postoperative nausea and vomiting.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Janssen recruits Debbie Allen for T2 Diabetes

Actress, choreographer and "So You Think You Can Dance" judge Debbie Allen has signed on to participate with the drugmaker's type 2 diabetes awareness and wellness program.

Pfizer seeks wider Xeljanz indication

The company expects to file an sNDA for plaque psoriasis next year.

Recalls dent Stryker Q1 earnings

Sales rose 5% compared to the same period last year.